Your browser doesn't support javascript.
Mostrar: 20 | 50 | 100
Resultados 1 - 6 de 6
Filtrar
1.
Cell Host Microbe ; 27(6): 879-882.e2, 2020 06 10.
Artigo em Inglês | MEDLINE | ID: covidwho-1719463

RESUMO

The inflammatory response to SARS-coronavirus-2 (SARS-CoV-2) infection is thought to underpin COVID-19 pathogenesis. We conducted daily transcriptomic profiling of three COVID-19 cases and found that the early immune response in COVID-19 patients is highly dynamic. Patient throat swabs were tested daily for SARS-CoV-2, with the virus persisting for 3 to 4 weeks in all three patients. Cytokine analyses of whole blood revealed increased cytokine expression in the single most severe case. However, most inflammatory gene expression peaked after respiratory function nadir, except expression in the IL1 pathway. Parallel analyses of CD4 and CD8 expression suggested that the pro-inflammatory response may be intertwined with T cell activation that could exacerbate disease or prolong the infection. Collectively, these findings hint at the possibility that IL1 and related pro-inflammatory pathways may be prognostic and serve as therapeutic targets for COVID-19. This work may also guide future studies to illuminate COVID-19 pathogenesis and develop host-directed therapies.


Assuntos
Infecções por Coronavirus/genética , Infecções por Coronavirus/imunologia , Pneumonia Viral/genética , Pneumonia Viral/imunologia , Adulto , Idoso , Variação Biológica Individual , COVID-19 , Análise por Conglomerados , Infecções por Coronavirus/sangue , Infecções por Coronavirus/patologia , Citocinas/sangue , Regulação da Expressão Gênica , Humanos , Masculino , Pandemias , Pneumonia Viral/sangue , Pneumonia Viral/patologia , Transcriptoma , Regulação para Cima
2.
Rev Med Virol ; 31(6): e2234, 2021 11.
Artigo em Inglês | MEDLINE | ID: covidwho-1574124

RESUMO

The coronavirus disease (Covid-19) pandemic is the most serious event of the year 2020, causing considerable global morbidity and mortality. The goal of this review is to provide a comprehensive summary of reported associations between inter-individual immunogenic variants and disease susceptibility or symptoms caused by the coronavirus strains severe acute respiratory syndrome-associated coronavirus, severe acute respiratory syndrome-associated coronavirus-2, and two of the main respiratory viruses, respiratory syncytial virus and influenza virus. The results suggest that the genetic background of the host could affect the levels of proinflammatory and anti-inflammatory cytokines and might modulate the progression of Covid-19 in affected patients. Notably, genetic variations in innate immune components such as toll-like receptors and mannose-binding lectin 2 play critical roles in the ability of the immune system to recognize coronavirus and initiate an early immune response to clear the virus and prevent the development of severe symptoms. This review provides promising clues related to the potential benefits of using immunotherapy and immune modulation for respiratory infectious disease treatment in a personalized manner.


Assuntos
COVID-19/imunologia , Síndrome da Liberação de Citocina/imunologia , Predisposição Genética para Doença , Influenza Humana/imunologia , Infecções por Vírus Respiratório Sincicial/imunologia , Síndrome Respiratória Aguda Grave/imunologia , Antivirais/uso terapêutico , Variação Biológica Individual , COVID-19/genética , COVID-19/virologia , Síndrome da Liberação de Citocina/tratamento farmacológico , Síndrome da Liberação de Citocina/genética , Síndrome da Liberação de Citocina/virologia , Expressão Gênica , Humanos , Imunidade Inata , Fatores Imunológicos/uso terapêutico , Influenza Humana/tratamento farmacológico , Influenza Humana/genética , Influenza Humana/virologia , Lectina de Ligação a Manose/genética , Lectina de Ligação a Manose/imunologia , Orthomyxoviridae/efeitos dos fármacos , Orthomyxoviridae/imunologia , Infecções por Vírus Respiratório Sincicial/tratamento farmacológico , Infecções por Vírus Respiratório Sincicial/genética , Infecções por Vírus Respiratório Sincicial/virologia , Vírus Sinciciais Respiratórios/efeitos dos fármacos , Vírus Sinciciais Respiratórios/imunologia , Coronavírus Relacionado à Síndrome Respiratória Aguda Grave/efeitos dos fármacos , Coronavírus Relacionado à Síndrome Respiratória Aguda Grave/imunologia , SARS-CoV-2/classificação , SARS-CoV-2/efeitos dos fármacos , SARS-CoV-2/imunologia , Síndrome Respiratória Aguda Grave/tratamento farmacológico , Síndrome Respiratória Aguda Grave/genética , Síndrome Respiratória Aguda Grave/virologia , Receptores Toll-Like/genética , Receptores Toll-Like/imunologia , Tratamento Farmacológico da COVID-19
3.
Diabetes Metab Syndr ; 15(5): 102246, 2021.
Artigo em Inglês | MEDLINE | ID: covidwho-1356198

RESUMO

Treatment related fluctuation (TRF) poses a special challenge in the treatment of Guillain-Barre syndrome (GBS). Many cases of GBS following COVID-19 infection have been reported in literature till date, but treatment related fluctuation (TRF) in post COVID-19 GBS has not been reported till date. We report a 35-year-old male patient who developed GBS following COVID-19 infection and had TRF after intravenous immunoglobulin (IV-IG) therapy. He required ventilator support but repeat IV-IG therapy led to complete recovery. Significant proximal muscle involvement, cranial nerve palsy, no antecedent diarrhea and absence of anti-GM1 antibodies are important predictors of TRF in GBS and need to be recognized early in the course of this illness. Early recognition of TRF and differentiating it from other forms of immune mediated neuropathy such as acute onset chronic inflammatory demyelinating polyradiculoneuropathy (A-CIDP) are important for prognostication and management.


Assuntos
COVID-19/complicações , Síndrome de Guillain-Barré/etiologia , Síndrome de Guillain-Barré/terapia , Imunoglobulinas Intravenosas/uso terapêutico , Adulto , Variação Biológica Individual , COVID-19/diagnóstico , COVID-19/etiologia , COVID-19/terapia , Síndrome de Guillain-Barré/diagnóstico , Humanos , Índia , Masculino , Neurônios Motores/fisiologia , Condução Nervosa/fisiologia , Prognóstico , Resultado do Tratamento , Neuropatias Ulnares/diagnóstico , Neuropatias Ulnares/etiologia , Neuropatias Ulnares/terapia , Síndrome de COVID-19 Pós-Aguda
4.
J Med Virol ; 93(2): 760-765, 2021 02.
Artigo em Inglês | MEDLINE | ID: covidwho-1196398

RESUMO

Coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 emerged in China in December 2019 and then rapidly spread worldwide. Why COVID-19 patients with the same clinical condition have different outcomes remains unclear. This study aimed to examine the differences in the phenotype and functions of major populations of immune cells between COVID-19 patients with same severity but different outcomes. Four common type adult inpatients with laboratory confirmed COVID-19 from Beijing YouAn Hospital, Capital Medical University were included in this study. The patients were divided into two groups based on whether or not COVID-19 polymerase chain reaction (PCR)-negative conversion occurred within 3 weeks. Peripheral blood samples were collected to compare the differences in the phenotype and functions of major populations of immune cells between the two groups of patients. The result shows that the proportions of CD3+ CD8+ CD38+ HLA-DR+ CD27- effector T killer cells generally declined, whereas that of CD3+ CD4+ CD8+ double-positive T cells (DPTs) increased in the persistently PCR-positive patients. In summary, considering the imbalance between effector T killer cells/CD3+CD4+CD8+ DPTs was a possible key factor for PCR-negative conversion in patients with COVID-19.


Assuntos
Variação Biológica Individual , Linfócitos T CD4-Positivos/imunologia , Linfócitos T CD8-Positivos/imunologia , COVID-19/patologia , Células T Matadoras Naturais/imunologia , SARS-CoV-2/patogenicidade , Adulto , Idoso , Antígenos CD/genética , Antígenos CD/imunologia , Linfócitos T CD4-Positivos/virologia , Linfócitos T CD8-Positivos/virologia , COVID-19/imunologia , COVID-19/virologia , Teste para COVID-19 , Feminino , Expressão Gênica , Antígenos HLA-DR/genética , Antígenos HLA-DR/imunologia , Humanos , Imunidade Inata , Imunofenotipagem , Contagem de Linfócitos , Masculino , Pessoa de Meia-Idade , Células T Matadoras Naturais/virologia , Fenótipo , Reação em Cadeia da Polimerase Via Transcriptase Reversa , SARS-CoV-2/genética , Índice de Gravidade de Doença
5.
Curr Res Transl Med ; 69(2): 103276, 2021 05.
Artigo em Inglês | MEDLINE | ID: covidwho-1062581

RESUMO

BACKGROUND: Understanding the spectrum and course of biological responses to coronavirus disease 2019 (COVID-19) may have important therapeutic implications. We sought to characterise biological responses among patients hospitalised with severe COVID-19 based on serial, routinely collected, physiological and blood biomarker values. METHODS AND FINDINGS: We performed a retrospective cohort study of 1335 patients hospitalised with laboratory-confirmed COVID-19 (median age 70 years, 56 % male), between 1st March and 30th April 2020. Latent profile analysis was performed on serial physiological and blood biomarkers. Patient characteristics, comorbidities and rates of death and admission to intensive care, were compared between the latent classes. A five class solution provided the best fit. Class 1 "Typical response" exhibited a moderately elevated and rising C-reactive protein (CRP), stable lymphopaenia, and the lowest rates of 14-day adverse outcomes. Class 2 "Rapid hyperinflammatory response" comprised older patients, with higher admission white cell and neutrophil counts, which declined over time, accompanied by a very high and rising CRP and platelet count, and exibited the highest mortality risk. Class 3 "Progressive inflammatory response" was similar to the typical response except for a higher and rising CRP, though similar mortality rate. Class 4 "Inflammatory response with kidney injury" had prominent lymphopaenia, moderately elevated (and rising) CRP, and severe renal failure. Class 5 "Hyperinflammatory response with kidney injury" comprised older patients, with a very high and rising CRP, and severe renal failure that attenuated over time. Physiological measures did not substantially vary between classes at baseline or early admission. CONCLUSIONS AND RELEVANCE: Our identification of five distinct classes of biomarker profiles provides empirical evidence for heterogeneous biological responses to COVID-19. Early hyperinflammatory responses and kidney injury may signify unique pathophysiology that requires targeted therapy.


Assuntos
Biomarcadores/sangue , COVID-19/diagnóstico , COVID-19/epidemiologia , COVID-19/fisiopatologia , Idoso , Idoso de 80 Anos ou mais , Variação Biológica Individual , Temperatura Corporal , COVID-19/sangue , Estudos de Coortes , Comorbidade , Testes Diagnósticos de Rotina , Progressão da Doença , Feminino , Frequência Cardíaca/fisiologia , Humanos , Masculino , Pessoa de Meia-Idade , Consumo de Oxigênio/fisiologia , Prognóstico , Estudos Retrospectivos , Medição de Risco , SARS-CoV-2/imunologia , SARS-CoV-2/patogenicidade , Índice de Gravidade de Doença , Fatores Socioeconômicos , Reino Unido/epidemiologia
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA